Showing results (11-20 of 28) with videos related to
Sort By:
Pageof 3
Blood|May 6, 2020
A hemophilia A mouse model for the in vivo assessment of emicizumab functionStephen Ferrière, Ivan Peyron, Olivier D Christophe, et al.Thrombosis and Haemostasis|July 25, 2024
An Inhibitory Single-Domain Antibody against Protein Z-Dependent Protease Inhibitor Promotes Thrombin Generation in Severe Hemophilia A and FXI DeficiencyClaire Auditeau, Tung-Son Nguyen, Floriane Devaux, et al.Haematologica|November 18, 2017
Complement C3 is a novel modulator of the anti-factor VIII immune responseJulie Rayes, Mathieu Ing, Sandrine Delignat, et al.Blood|September 4, 2025
A bispecific nanobody for the treatment of von Willebrand disease type 1Ivan Peyron, Caterina Casari, Genevieve McCluskey, et al.Haematologica|November 28, 2024
A fully humanized von Willebrand disease type 1 mouse model as unique platform to investigate novel therapeutic optionsGenevieve McCluskey, Marco Heestermans, Ivan Peyron, et al.Thrombosis and Haemostasis|June 30, 2026
Anti-TFPI Single-Domain Antibodies: Novel Rebalancing Therapies for Hemophilia and Other Rare Bleeding DisordersClaire Auditeau, Elsa P Bianchini, Ivan Peyron, et al.Plos One|August 23, 2013
IVIg treatment reduces catalytic antibody titers of renal transplanted patientsAnkit Mahendra, Ivan Peyron, Cécile Dollinger, et al.Haematologica|April 3, 2025
Consistent clinical factor VIII equivalency is unlikely for non-factor therapies in hemophilic miceThibaud Sefiane, Geneviève McCluskey, Marie Clavel, et al.Journal of Thrombosis and Haemostasis : JTH|July 20, 2023
Imlifidase, a new option to optimize the management of patients with hemophilia A on emicizumabMelissa Bou-Jaoudeh, Angelina Mimoun, Sandrine Delignat, et al.Journal of Immunology (Baltimore, Md. : 1950)|April 13, 2016
Generation of Catalytic Antibodies Is an Intrinsic Property of an Individual's Immune System: A Study on a Large Cohort of Renal Transplant PatientsAnkit Mahendra, Ivan Peyron, Olivier Thaunat, et al.Pageof 3